MRNA

Moderna's stock price has experienced significant volatility and growth in the past six months, rising 147.83% from $52.66 on August 3, 2026, to $208.90 on September 29, 2026, and reaching a new 52-week peak of $225.00 on October 9, 2026, representing a 738.61% increase over the last 12 months. Key events include its inclusion in the Nasdaq-100 Index on October 9, 2026, replacing Warner Bros. Discovery, which is expected to boost visibility and passive demand. Optimism was fueled by promising late-stage mRNA vaccine trial results, particularly for its personalized cancer vaccine collaboration with Merck. On September 30, 2026, the stock saw a premarket sell-off after Moderna created a new Chief Operating Officer role and rehired veteran Juan Andres, with long-time operations leader Jerh Collins set to retire. A federal judge in Delaware declined to dismiss patent lawsuits brought by Bayer's Monsanto unit against Moderna, Pfizer, and BioNTech, related to mRNA technology. Analyst ratings included Morgan Stanley raising its price target from $89 to $95, Evercore ISI lifting its target to $80, while Bernstein reiterated a Market Perform rating and UBS maintained a Neutral rating.